



HAL
open science

Pricing and Patents of HIV/AIDS Drugs in Developing Countries

Joan-Ramon Borrell

► **To cite this version:**

Joan-Ramon Borrell. Pricing and Patents of HIV/AIDS Drugs in Developing Countries. *Applied Economics*, 2007, 39 (04), pp.505-518. 10.1080/00036840500438954 . hal-00581931

HAL Id: hal-00581931

<https://hal.science/hal-00581931>

Submitted on 1 Apr 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Pricing and Patents of HIV/AIDS Drugs in Developing Countries

Journal:	<i>Applied Economics</i>
Manuscript ID:	APE-05-0200
Journal Selection:	Applied Economics
Date Submitted by the Author:	08-Apr-2005
JEL Code:	L11 - Production, Pricing, and Market Structure Size Distribution of Firms < L1 - Market Structure, Firm Strategy, and Market Performance < L - Industrial Organization, L51 - Economics of Regulation < L5 - Regulation and Industrial Policy < L - Industrial Organization, L65 - Chemicals Rubber Drugs Biotechnology < L6 - Industry Studies: Manufacturing < L - Industrial Organization, O34 - Intellectual Property Rights: National and International Issues < O3 - Technological Change Research and Development < O - Economic Development, Technological Change, and Growth
Keywords:	Patents, Pricing, Pharmaceuticals, HIV, AIDS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pricing and Patents
of HIV/AIDS Drugs
in Developing Countries

Joan-Ramon Borrell
(University of Barcelona)*

January, 2005

* I thank Jayashree Watal's leading role and support, and Dani Rodrik's encouragement in the implementation of the CID project on studying the impact of patents on the access, pricing and availability of HIV/AIDS drugs in developing countries. I gratefully acknowledge the comments from Albert Saiz and many participants at Harvard, NBER, Carlos III, and Vigo Seminars. I was a post-doctoral fellow at Harvard Economics Department while working on this paper. I thank my host and Ariel Pakes kindly supervision. I gratefully acknowledge funding from the CID, and unrestricted educational grants from *Fundacion Ramon Areces* (Madrid, Spain) and The Merck Foundation, the philanthropic arm of Merck & Co. Inc., Whitehouse Station (New Jersey, USA). The opinions stated are only those of the author, and any error or omission remains the author's sole responsibility. E-mail: jrborrell@ub.edu

Abstract

This paper provides empirical evidence on the impact of patents on drug prices across developing countries. It uses sales data on HIV/AIDS drugs in a sample of 34 low and middle-income countries between 1995 and mid-2000. The main findings are that patents do shift drug prices up, that drug prices are correlated to per capita income levels, and that drug firms follow a skimming strategy when pricing new HIV/AIDS drugs. That is, there is across country and intertemporal price discrimination in the global drug markets.

Keywords: Patents; Pricing; Pharmaceuticals; AIDS.

JEL Codes: L11; L51; L65; O34.

1 Introduction

The impact of patents on drug prices has emerged as a controversial issue in the face of the Human Immunodeficiency Virus (HIV) public health crisis. Activists blame patents for keeping prices out of the reach of those who badly need new drugs called antiretroviral drugs (ARV), and lobby strongly for letting generics compete with original brand products protected by patents in developing countries. ARV drugs are effective and safe drugs that have changed the late stage of the HIV infection, the Acquired Immune Deficiency Syndrome (AIDS), from a death sentence to a chronic disease. Drug firms argue that patents are not a barrier to access to the new drug therapy, because of tiered or compassionate pricing, and that patents are key mechanisms to encourage research and development of new medicines and vaccines.

Most of the studies on patents and pricing focus on the effect of patent expiration on drug pricing and shares in the US: Hurwitz and Caves (1988); Caves, Whinston and Hurwitz (1991); Grabowski and Vernon (1992); Frank and Salkever (1992, 1997); Griliches and Cockburn (1994); Hellerstein (1994) and, Fisher and Griliches (1995). Hudson (1992 and 2000) analyzes drug pricing dynamics and patent expiration not only in the US, but also in the UK, Germany, France, and Japan. A common finding

1
2
3 of these papers is that the larger the numbers of competitors, the lower drug prices are,
4
5 and that brand name products might even increase in price after the introduction of
6
7 generics. This is what Scherer (1993) named the “generic paradox.”
8
9

10
11 Very little attention has been devoted to studying the impact of patent rights on
12
13 drug pricing in developing countries. Some papers attempt to simulate the likely effects
14
15 of product patents on average drug prices in developing countries. In the cases of
16
17 Argentina and India, Challu (1991), Fink (2000), and Watal (2000) obtain impacts of
18
19 patents on average prices of a different order. Impacts of about 200% are obtained by
20
21 using the assumptions that yield the highest impact and of 26% (Watal, 2000), or as low
22
23 as 12% (Fink, 2000), with the assumptions that yield the lowest impact. Using less
24
25 detailed data, Maskus and Eby-Konan (1994) and Subramanian (1995) obtain maximum
26
27 price increases of up to 67% due to the introduction of pharmaceutical product patent
28
29 rights.
30
31
32
33

34
35 Another stream of works has focused on studying the dynamics of drug pricing.
36
37 Lu and Comanor (1998) described that there are two different pricing strategies in the
38
39 drug markets. The pricing strategy named “skimming strategy” corresponds to what Lu
40
41 and Comanor (1998) found to be the pricing strategy for the subset of drugs which
42
43 represent important therapeutic gains, as opposed to the “penetration strategy” that Lu
44
45 and Comanor (1998) found to be the pricing strategy for the subset of drugs which
46
47 largely duplicate the actions currently available products.
48
49
50

51
52 In the skimming strategy cases, drug firms introduce their products at high price
53
54 which later on declines. In the penetration strategy cases, drug firms introduce their
55
56 products at low price which later on increases. The literature on experience goods (those
57
58 whose users determine product attributes only by using the product) explains when
59
60 pioneering brands try to build up their consumer base and their reputation by a low/high

1
2
3 pricing sequence (Schmalensee, 1982), and also when monopolists prefer instead to “milk
4 its reputation” using a high/low pricing sequence (Shapiro, 1983). The key issue in this
5 literature is the buyer’s perceptions of the new product quality. When consumers are
6 pessimistic regarding the product quality, the firms needs to build the reputation of the
7 product largely by setting a low introductory price followed by a higher regular price.
8 When consumers overestimate product quality, the firm will optimally set a high launch
9 price but then lower its price over time.¹

10
11
12
13
14
15
16
17
18
19
20 This paper tries to fill part of the gap in the empirical literature on drug pricing. It
21 investigates the impact of patents on pricing of HIV/AIDS drugs in a sample of low and
22 middle-income countries in the late 1990’s. This is a companion paper to that by Borrell
23 and Watal (2002) on studying patents and access to HIV/AIDS drugs. The hypothesis is
24 that drug prices are higher under patent regimes. Patents legally prevent unauthorized
25 manufacture, sale, importation, and using or stocking for sale of the patented product
26 during a limited term. Patents prevent competition between the innovator of the drug
27 (and any of its licensees) and the imitators (unauthorized providers). Patents prevent
28 competition between providers of products that contain the same therapeutically active
29 substance, and that only differ slightly in other characteristics. The lack of such close
30 competitors is expected to shift prices upward.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46 Additionally, this paper studies how the pricing dynamics differ across patent
47 regimes. We expect pricing strategies to differ strongly across patent regimes. Patents
48 allow drug firms to get the most from skimming and penetration strategies. By contrast,
49 pricing in no-patent regimes will be more closely linked to the dynamics of production
50 costs and competition.

51
52
53
54
55
56
57
58
59
60
¹ Bagwell and Riordan (1991) analyze the case in which the firms signal high quality new products with prices that are above full information profit maximizing prices. As information about the prices diffuses, the price distortion disappears.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This paper uses sales data on HIV/AIDS drugs in a sample of 34 low and middle- income countries, between 1995 and mid-2000, and reduced form regressions to empirically assess the impact of market exclusivity on pricing of clinically tested ARV drug bundle (so called “cocktail therapy”).

Our main finding is that the daily dose price of any “cocktail therapy” differs significantly in two dimensions: (1) drug bundles are on average more expensive when they include products under patent regime, and (2) drug bundles are on average more expensive when they include products under licenses from the firm that originally developed the drug. We also find a positive relationship between drug prices and per capita income in both patent and non-patent regimes. This finding suggests, that not only competition under non-patent regimes drives drug prices to be related to per capita income across countries, but also that multinational drug firms have effectively tiered their prices to per capita income across countries when drugs are under patent regime.

Finally, we find that drug firms set a very high initial price and then lower it over time during the 9-year period after the date the drug bundle was available on the US market only in patent regimes. This pricing strategy, named skimming pricing (as opposed to penetration pricing), corresponds to what Lu and Comanor (1998) found to be the pricing strategy for drugs, which represent important therapeutic gains. Competition prevents price discrimination in no-patent regimes.

This paper is organized in the following way: section 2 describes the method we follow to test whether patents have a positive or negative effect on pricing, and the characteristics of the data set. Section 3 offers some descriptive statistics on patents and prices. Section 4 shows the results of estimating the impact of patents on pricing. Section 5 concludes.

2 Methodology and Data

2.1 Methodology

There are large number of studies in economics that use natural experiments or quasi-experiment designs to examine outcome measurements for observations in treatment groups and comparison groups. Meyer (1995) describes the strengths and weaknesses of using quasi-experiments in economics. Among good natural experiments, Meyer (1995) cites those induced by policy changes that may allow a researcher to obtain exogenous variation in the main explanatory variables.

This paper uses the difference approach in a quasi-experiment to study how the outcome of interest – i.e. drug pricing, – differs for treatment groups and comparison groups that are not randomly assigned. The treatment group contains all the country-drug pairs for which any ARV drug, in the country of a sample of developing countries, is under a patent regime, while the comparison group contains all the country-drug pairs for which the drug is not under a patent regime. Quasi-experiments allow us to distinguish the effects of exogenous variation in an explanatory variable that is, in other situations, endogenously related to the outcome of interest. The estimates of the effect of patents on drug prices are usually biased because drug firms apply for patent status across countries and drugs in a non-random way. Drug firms apply and renew the patent status of a particular drug in a given country only when both of the two following conditions hold: (1) when the firm may legally obtain a patent right from the government of that particular country (what we will refer to as the “patent regime”) for the drug and (2) when the present discounted value of the expected cash flow of patenting that drug in that country is positive (what we will refer to as the firm “patenting decision”).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This paper overcomes the bias by studying the effect of a policy change on the patent regime of a set of HIV/AIDS drugs and country pairs on the outcome of interest – i.e. drug pricing. The key identifying assumption in the study is that differences in patent regimes across drug-country pairs are exogenous with respect to the outcomes in the market for ARV drugs. The paper sustains that patent law changes in the countries sampled were driven mainly by bilateral or international agreements and national developments, rather than by concerns related to the treatment of HIV patients.

As Meyer (1995) highlights, three of the main goals of the research design should be: (1) having a large enough variation in the key explanatory variables so that it is exogenous, (2) finding comparison groups that are comparable, (3) probing the implications of the hypotheses under test.

With respect to the first issue, this paper identifies the factors that drove changes in the patent regime to rule out obvious sources of endogeneity. Each drug-country patent regime indicator depends on two data: (1) whether patent protection is locally available and, (2) when the innovator can apply for patent protection in any of the World Trade Organization (WTO) member countries. The differences in patent regimes across countries, and the timing of the invention of the 14 different ARV molecules (from 1985 to 1995) lead to an appropriate mix of patent regimes across drug-country-pairs.

With respect to the second issue, this paper uses different regression specifications including different sets of controls to avoid the possibility of omitted variables, trends in outcomes and omitted interactions to examine the comparability of treatment groups and comparison groups. In the regression analysis, we treat omitted variables, trends in outcomes and omitted interactions by controlling for relevant country characteristics, and also country, brand licensing status (licensed brands versus non-licensed brands), pharmaceutical form, and annual fixed effects, and country and year

interactions. Additionally, the empirical literature on drug markets draws our attention to the additional need for controlling differences in observed drug qualities such as dosage, efficacy, and side effects.²

The following regression equation provides a simple and parsimonious way to control observable differences in the observations of different groups,

$$p_{jt}^i = \alpha + \alpha_t^i + \beta r_j^i + z_t^i \delta_1 + z_j \delta_2$$

where p_{jt}^i is the price of the daily dose of a single, double or triple drug bundle j in country i in year t , α_t^i are fixed effects for country i and year t , r_j^i is the patent regime of the drugs of the bundle j in country i , and β is the true causal effect of the treatment on the outcome. The regression controls for country and year characteristics (z_t^i), and also for drug bundle characteristics (z_j). The regression equation adjusts for observable differences between the observations in the different groups.

With respect to the third issue, the paper further probes for hypotheses by testing whether the causal effect of the patent regime holds in different settings: for single, double and triple drug bundles separately, and for countries with variation in drug patent

² The empirical literature that studies specific drug markets shows that we should control dosage, efficacy, toxicity, and side effects among other observed qualities: Berndt, Griliches and Rosset (1993) study antihypertensive drugs; Berndt *et al.* (1995), and Berndt, Pindyck and Azoulay (1999 and 2000) focus on anti-ulcer drugs; Berndt, Cockburn and Griliches (1996) analyze antidepressant drugs; and Cockburn and Anis (1998) arthritis drugs. We do not have enough data on differences in drug toxicity among ARV's although higher life-threatening toxicity has been related to the use of a type of ARV, the so-called Nucleoside Reverse Transcriptase Inhibitors (NRTI). Therefore, at least drug fixed effects take care of fixed differences in toxicity across drug types.

1
2
3 regimes separately. In any regression equation, the restriction that δ_1 and δ_2 are equal
4
5
6 across groups is important because otherwise the regression equation will not adjust for
7
8 differences in control variables across groups.
9

10
11 Scherer and Watal (2001) estimated reduced form pricing equations across
12
13 countries and time by using this same data set. They found a significant negative impact
14
15 of patent rights on average leading multinational prices. They qualified this result as
16
17 ‘anomalous’ and driven by: (1) measurement error, or (2) complex interrelationships
18
19 between patent and other variables.
20
21

22
23 This study of the impact of patent on prices differs from that conducted by
24
25 Scherer and Watal (2001) in three aspects. First, we study the effect of the patent regime
26
27 indicator on all firms pricing, not only on multinationals. Second, the patent regime
28
29 indicator has been improved with respect to that used by them. It includes data on patent
30
31 rights, exclusive marketing rights (EMR), and ‘pipeline protection’ available to innovators
32
33 across countries and drugs as explained below. Finally, instead of regressing the price of
34
35 each product on a set of country and drug effects, we regress the price of each clinically
36
37 tested bundle of drugs available in any given country and year, on a set of characteristics
38
39 including the patent regime indicator. This is important because ARV drugs have strong
40
41 complementarities in consumption. Effective therapies are usually cocktail therapies
42
43 combining two or three different drugs. Equilibrium prices are likely to be related to the
44
45 dosage, efficacy and adverse reactions of each bundle of drugs that is actually available to
46
47 the AIDS patients in a given country and year.
48
49
50
51
52

53 54 55 56 57 58 59 60 2.2 Data

Treatment of AIDS in rich countries changed dramatically after 1995, when new, more
effective, and safer drugs were approved. According to Henkel (1999), the combination

1
2
3 of the new ARV drugs with the older ones (“cocktail therapy”) “has helped change AIDS
4 in the last three years from being an automatic death sentence to what is now often a
5 chronic, but manageable, disease.” As Table 1 shows, 14 different products containing
6 one molecule, and one product combining two molecules (i.e. a total of 15 products),
7 were available in the US by June 2000.
8
9

10
11
12
13
14
15
16 IMS, the leading collector of data on drug sales world-wide, provided us with annual
17 sales data for the 15 ARV’s in 21 different countries and two country groupings, viz.
18 French West Africa and Central America, between January 1995 and June 2000.³ IMS
19 data consist of unsubsidized annual wholesale sales and revenue estimates corresponding
20 to each particular drug presentation sold at retail outlets between 1995 and mid-2000,
21 except in 4 cases. IMS reports total aggregated retail and hospital sales (R&H) in South
22 Africa, Thailand, the Philippines, and Indonesia. IMS data refer only to unsubsidized
23 sales. They do not include subsidized distribution of drugs to patients (particularly
24 important in Brazil and Thailand), nor do they include any donations of drugs.⁴ Using
25
26
27
28
29
30
31
32
33
34
35

36
37
38 ³ IMS provided us with aggregated sales data for two supranational entities: French West Africa,
39 comprising aggregate sales in Benin, Cameroon, Democratic Republic of Congo, Ivory Coast,
40 Gabon, Guinea and Senegal; and, Central America, including Costa Rica, El Salvador, Guatemala,
41 Honduras, Nicaragua, and Panama. All economic indicators for those two supranational entities
42 are population weighted averages of the national indicators. The data set includes annual data
43 referring to the calendar years from 1995 to 1999, and also to the year from July 1999 to June
44 2000.
45
46
47
48
49
50
51

52
53 ⁴ For each drug presentation, IMS reports data by year, country, molecule, firm, brand name,
54 pharmaceutical form, strength, and pack size. Sales revenues obtained from each package or
55 presentation at the wholesale level are reported in current \$US. Physical sales are reported in
56 standard units (number of tablets, vials or teaspoons). IMS did not provide us with sales of the
57 active ingredient in milligrams, or in daily doses.
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

IMS data, we compute sales in milligrams for each presentation. We collected data on the minimum recommended milligrams for completing a daily dose of our 15 drugs from WHO (2000) and PDR-CG (2000). Combining this information, we computed sales in terms of the number of daily single-drug treatment dose. We then obtained the price per daily single-drug treatment dose by dividing revenues in \$US by sales in the number of daily treatment doses.

Patent protection on pharmaceuticals changed substantially in the countries of our sample due to the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Before January 1st 1995, 14 countries in our sample did not grant product patents.⁵ Between 1996 and 2000, eight of those countries introduced patent protection for pharmaceuticals.⁶

Under TRIPS, WTO member countries were obliged to allow for the filing of product patents for pharmaceuticals by 1st January 1995 and the subsequent grant of either product patents or exclusive marketing rights for eligible pharmaceutical products.⁷

⁵ These were Argentina, Bangladesh, Brazil, Colombia, Egypt, Guatemala, Guinea, India, Morocco, Pakistan, Peru, Tunisia, Uruguay and Venezuela. Pakistan had a patent law in force, but an executive order disallowed pharmaceutical patents.

⁶ Colombia, Ecuador and Venezuela introduced product patents in 1996; Brazil in 1997; Argentina in 1999; Guinea, Guatemala, and Morocco in 2000. We focus on product patents (exclusivity related to therapeutically active ingredient) rather than process patents (exclusivity related to the method of obtaining such an active ingredient). Process patents, like other type of patents on therapeutic uses, pharmaceutical forms, and so on, are important but accessory ways of protecting the main and broader exclusivity right of the innovator, that protecting the therapeutic active ingredient from being copied and sold.

⁷ When product patents are not available as of 1st January 1995, WTO members have to provide a system whereby drug patent applications can be filed (often referred to as a “mailbox” system).

1
2
3 Developing countries were allowed up to 1st January 2005, and the least-developed
4 countries up to 1st January 2006 (and now up to 2016 under the Doha Ministerial
5 Declaration on the TRIPS Agreement and Public Health) so as to formally change patent
6 laws to introduce pharmaceutical product patent protection. Furthermore, those lesser-
7 developed countries may obtain further extensions from WTO on a case-by-case basis.
8
9

10
11
12
13
14
15 In the countries not providing patents to eligible drugs before 1st January 1995,
16 TRIPS obligations do not affect drugs that were no longer “new” for patenting purposes
17 as of the date of filing in that country, or as of the date of priority accorded to them
18 upon request. Therefore, we can conclude that all WTO Members would be obliged to
19 make patents (or exclusive marketing rights) available to inventions for which the first
20 patent application was made in any WTO member on or after 1st January 1994.⁸
21
22
23
24
25
26
27
28
29
30

31 “Mailbox” applications do not have to be examined until the local patent law is passed. However,
32 when a drug subject to a “mailbox application” obtains marketing approval before the local
33 patent office makes a decision on whether granting a patent right or not, the following special
34 rule applies: An Exclusive Marketing Right (EMR) of up to five years (or until the patent is
35 granted or rejected, whichever is shorter) must be granted from the date of local marketing
36 approval, provided that a patent has been filed for that drug and a patent and marketing approval
37 obtained in another WTO member country after 1st January 1995.
38
39
40
41
42
43
44
45

46 ⁸ An invention is considered to be new if it does not form part of the state of the art. The “state
47 of the art” is generally defined, as everything made available to the public by means of a written
48 or oral description, by use, or in any other way, before the date of filing of the patent application.
49 Under WTO rules, incorporating existing WIPO (World Intellectual Property Organization)
50 conventions, for purposes of determining novelty, patent applicants may claim the priority of an
51 earlier application made during the period of 12 months from the date of filing. It is theoretically
52 possible to have a patent applicant not to claim priority from the date of an earlier filing and to
53 claim that products for which patent applications were filed elsewhere from say, mid-1993 are
54
55
56
57
58
59
60

1
2
3 We lacked direct data on patents granted for each of the 14 different ARV
4 molecules in each country. Therefore, we assessed instead the patent regime for each
5 drug-country pair. We gathered information on whether product patents for
6 pharmaceuticals were available in each country for a year after each ARV product patent
7 application was filed in according to the key priority date given in the US.
8
9

10
11
12
13
14
15 Balasubramaniam (2000) provides the date of filing of the patent application,
16 which the US Patent and Trademark Office reports as the key patent for each ARV.⁹
17 Using a variety of sources, including local legislation and the complete cross-country
18 data-set compiled by Qian (2001), we obtained the hypothetical date from which patent
19 protection for pharmaceuticals could have been granted for each drug in each one of the
20 34 countries of our sample.
21
22
23
24
25
26
27
28
29

30 We built up the patent regime indicator using the key patent priority date and the
31 date from which each country could have granted patent protection. For each drug-
32 country-pair, we assessed whether product patents would have been available locally
33 within a year from the key priority date of each molecule. TRIPS provisions on exclusive
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

novel (since later than this date the application would then be published by another patent office after 18 months and so would no longer be novel as of or after January 1995), but we believe that this is unlikely to happen in practice.

⁹ The US Federal Food, Drug, and Cosmetics Act required that drug firms provide patent information with all new drug applications. Taking into account this information, the FDA sets the exclusivity term during which an abbreviated new drug application is not granted (a generic is not approved). The *Electronic Orange Book* (FDA, 2000) publishes the number of the appropriate patents claimed by the firms when the drugs are subject to approval. Using the patent numbers, Balasubramaniam (2000) obtained each ARV key priority date from the US Patent and Trademark Office online database (<http://www.uspto.gov>). We thank Mike Palmedo from the Consumer Project on Technology for explaining to us how this data was gathered.

1
2
3 marketing rights (EMR's) affect four of the 14 ARV molecules. For the following four
4 molecules, patent applications could have been filed after January 1st 1995 in all WTO
5 countries apart from the country where the priority date was set: Nelfinavir (key patent
6 priority date - February 2nd 1994); Delavirdine (key patent priority date – February 22nd
7 1994); Ritonavir (key patent priority date - April 25th 1995); Efavirenz (key patent priority
8 date - June 2nd 1995). We set the patent regime dummy variable to be 1 for these four
9 drugs in all countries in our sample because local governments would be obliged to
10 provide EMR or product patents to the innovators of these molecules under TRIPS
11 rules.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 Remember that the patent regime indicator does not report whether the
26 innovator was granted or had even applied for patent protection for each drug-country-
27 pair of our sample. In other words, it does not reflect the actual patent status of the drug.
28 It only shows that patent or other market exclusivity status was attainable for some years,
29 to the best of our knowledge. So, the patent regime is arguably exogenous to any firm
30 decision. Taking into account the value of patent protection, innovators may decide
31 whether or not it pays to apply in each one of the countries that make available such
32 rights.
33
34
35
36
37
38
39
40
41
42
43

44 Table 2 shows that Central America, French West Africa, Malaysia and South
45 Africa led the sample in the number of drugs for which patents could have been granted
46 by 2000. In these four countries or country groupings, the patent holders of all 15 ARV's
47 could apply for patents.¹⁰ In a second set of countries, patent laws have changed recently
48 to make product patents available for pharmaceuticals: Mexico (1991), Thailand (1992),
49
50
51
52
53
54

55
56
57 ¹⁰ Product patents for drugs have been granted in all Central American countries since the 1950s,
58 except in Guatemala where product patents were introduced in 2000. We set the patent regime
59 indicator to be equal to 1, in all the country-drug-pairs corresponding to Central America.
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Chile (1991) and Indonesia (1993). Mexico and Thailand led this second group of countries because they granted the so-called 'pipeline' protection when introducing legislation on product patents. In these countries, innovators could apply for patent protection for drugs in the 'pipeline', i.e. drugs not already marketed although not 'new' for patenting, when the new law came into force. Finally, in 14 countries in our sample, innovators could only apply for patents or EMR's for the 4 drugs affected by the TRIPS rules on 'mailbox applications'.

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Local prices of ARV drugs differ substantially from US prices across countries and time. Table 4 shows the wholesale minimum price per year of a set of clinically tested ARV therapies in any oral solid form (tablets, capsules, and the like): single-drug therapy; double-drug therapy and the so-called Highly Active Antiretroviral Therapy (HAART) three-drug therapy. At the top end, the lowest priced annual triple drug bundle per patient in 1999 was higher in Mexico (US\$ 8,149), Colombia (\$US 7,728), Chile (\$US 6,853) than in the US (\$US 6,770). At the bottom end, the minimum price per annual triple drug bundle is \$US 4,366 in South Africa and \$US 3,025 in Brazil. The last column in Table 4 shows that the minimum price per annual triple drug bundle in 1999 was higher than the per capita income in \$PPP in all the countries of the sample except in Brazil (47% of per capita income), Argentina (58%) and Chile (81%), while the minimum price was 21% of the per capita income in the US. All minimum prices of single and double drug bundles are smaller than the minimum price in the US, particularly in India, Thailand, Brazil, and South Africa.

53
54
55
56
57
58

We also matched each local product to an equivalent product in the US using data on the minimum list price in the US.¹¹ In 1995, sales weighted mean prices were

59
60

¹¹ As reported in the Red Book (1995, 1996, 1997, 1999 and 2000), the PDR-Generics (1997), and PDR-CG (1998, 1999 and 2000). We matched each local price with the US minimum

1
2
3 quite close to US wholesale list prices in current \$US in all countries for which data is
4 available. However, by mid-2000, prices dropped to one-half or less of US prices in five
5 countries: India, South Africa, Brazil, Malaysia and Thailand. Note that patents were
6 available for all drugs in S. Africa and in Malaysia and for most in Thailand. In eight
7 countries, prices dropped to levels of between 53% and 73% of the US prices. In
8 contrast, prices increased in Mexico and Venezuela, and did not decrease much in
9 Argentina and Colombia.

10
11 Table 5 also shows that local prices in terms of purchasing power parity (PPP)
12 were well above their US counterparts for all countries in 1995 (ranging from 118% to
13 394%). Between 1995 and 1999, relative local to US prices dropped in all countries
14 except in Mexico and Venezuela. However, by 1999, mean local prices in PPP terms
15 were higher than US prices in all countries (ranging from 106% to 286%) except Brazil
16 (60%).

17
18 What are the drivers of the pricing dynamics? Table 6 shows that the cumulative
19 annual decrease in the sales weighted mean price in current \$US between 1995 and 1999
20 (column 1) is driven by three factors: (1) the introduction of cheaper new products
21 particularly in India, Uruguay, French West Africa, and Malaysia (column 2); (2) the drop
22 in nominal prices in current \$US for the drugs already on the market, particularly in
23 Central America, the Philippines, South Africa, and Peru (column 3); which in turn is
24 mainly driven by (3) the depreciation of the exchange rate between the local, and the US
25 currency, particularly in the Philippines, South Africa, and Peru (column 4).

26
27 Table 7 shows that relative price indices in local currency (column 1) decreased in
28 all countries except Thailand, Malaysia, and Argentina. Patients benefited from lower
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

wholesale list price for each particular drug and pharmaceutical form pair between 1995 and
2000.

1
2
3 prices in local currencies because many firms were not able to increase nominal prices
4
5 (column 2) to offset the negative impact of local inflation (column 3).
6
7
8
9

10 **3 Results**

11
12
13
14 Table 8 shows summary statistics of the variables used in the regression analysis. The
15
16 dependent variable in the pricing regressions is the log of the price per daily dose of any
17
18 clinically tested drug bundle available to patients in any country, in any year. There are
19
20 2,459 clinically proven one-drug, two-drug, or three-drug bundles available to AIDS
21
22 patients in our data set. The right hand side variables of interest in the pricing regressions
23
24 are the dummies that are equal to 1 when (1) the bundles include at least one original
25
26 drug in a patent regime, (2) when the bundles includes at least one original drug in a no-
27
28 patent regime, and (3) when the bundles includes at least a generic in a patent regime.
29
30 The omitted category is the case when all the drugs in the bundle are local copies
31
32 introduced in no patent regimes.
33
34
35
36

37
38 We control for different vectors of price shifters. Table 9 shows the results from
39
40 estimating different specifications of the pricing equation. In column (1) we include the
41
42 country mean income, the country income inequality, the dosage, the efficacy, the
43
44 adverse reactions of each bundle, and the fixed effects related to the number of years
45
46 since the drug bundle was available in the US (1...12), the number of drugs contained in
47
48 each bundle (1, 2 or 3), pharmaceutical form (oral solid, oral liquid, vials), years
49
50 (1995...1999), and a fixed effect for controlling when the data also includes hospital
51
52 sales. In column (2) we add a set of country fixed effects. In column (3), we add to this
53
54 latter specification a set of country-year pair effects. Table 10 shows the results of this
55
56 specification including country-year pair effects for single drug, double drug and triple
57
58 drug therapy separately. It is important to check the robustness of the results to the type
59
60

1
2
3 of drug therapy because when including double and triple therapies in the regression, we
4
5 might be introducing heterocedasticity of unknown form.
6
7

8
9 Results in table 9 and 10 do not differ much. As a larger number of drugs of the
10
11 bundle are under a patent regime, expected prices increase. This result becomes more
12
13 significant as we include country, year, and country-year pair fixed effects. The effect of
14
15 the patent regime variable grows as we go from single therapy to triple therapy.
16
17

18
19 Results in column 3 of table 9 allow us to compare expected prices. Panel A in
20
21 Table 11 shows that drug bundles containing at least one original drug in a patent regime
22
23 are on average priced 70% higher than drug bundles containing only local copies
24
25 marketed in no patent regimes.
26
27

28
29 Table 11 also shows that drug bundles containing at least one generics marketed
30
31 in a patent regime (probably when the drug goes off patent in country-drugs previously
32
33 under patent regime) are on average priced 22% higher than drug bundles containing
34
35 only local copies. Moreover, drug bundles containing at least one original drug are priced
36
37 16% higher than local copies even when it is introduced in no-patent regimes. Panels B,
38
39 C and D show the estimates of these price differences using the results in Table 10.
40
41

42
43 These results show that patients have access to cheaper drug bundles, and to a
44
45 wider range of prices in no-patent regimes i.e., drug bundles containing only cheaper
46
47 local or generic non-licensed brands rather than bundles containing more expensive big
48
49 pharma brands. That is the expected result from the competition among different firms
50
51 offering drugs that contain the same chemical entities on the market. For instance, we
52
53 observe that in a no-patent regime such as the corresponding to the country-drug pair
54
55 Argentina-Zidovudine eight firms compete offering close substitute brands.
56
57

58
59 Results also show that competition of just one generic firm at the end of the
60
patent term also induces a reduction of prices. For instance, a generic Canadian firm

1
2
3 introduced Zidovudine in Central America as a non-licensed brand after the exclusivity
4 term of the original developer ended. These results suggest that drug prices flatten out
5 only gradually as new competitors come in. Furthermore, these price differentials also
6 show that big pharma licensed brands are priced differently across patent regimes.
7
8
9
10
11

12
13 Tables 9 also show that the prices across countries are closely related to each
14 country per capita income and income inequality. More importantly, the positive link
15 between prices and mean income is persistent across patent regimes, and gets stronger
16 for drug bundles containing more drugs. The relationship between prices and income
17 inequality is ambiguous, probably because the functional form is too restrictive to handle
18 the non-linearity relationship between prices and income distribution. However, these
19 results are consistent with the assumption that price relatives depend not only on the
20 degree of differentiation among products on the market, but also on the income
21 distribution of each country, the characteristics of the outside good, and the marginal and
22 fixed costs of production.
23
24
25
26
27
28
29
30
31
32
33
34
35

36
37 Finally, tables 9 and 10 show that launch prices are very high, and that drug
38 bundle prices adjust down strongly. Figure one uses the results of a regression using
39 country-year fixed effects and allowing for different time trends for single, double and
40 triple therapies to predict the evolution of mean prices across the life cycle of the
41 products. The figure shows that drug firms use the so called “skimming strategy” when
42 pricing new drug in the case of original drugs in patent-regimes. This is the pricing
43 strategy named “skimming strategy.” More should be studied to understand the
44 fundamentals of this strategy, particularly, whether and why drug firms are discriminating
45 prices intertemporally and across countries.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4 Conclusions

Our main finding is that the average daily dose price of any ARV “cocktail therapy” differs significantly between the treatment group of country-drug pairs in which pharmaceutical firms may apply for product patent rights, and the comparison group of country-drug pairs in which pharmaceutical firms may not apply for product patent rights. We find that on average cocktail therapies are more expensive when they include big pharma licensed brand products.

Additionally, we find evidence of a persistent relationship between drug prices and per capita income under patent and no-patent regimes, and a strong decreasing trend in prices. Sales-weighted average ARV prices were quite close to US average prices in all countries by 1995. By mid-2000, these prices had dropped significantly in current \$US. However, ARV prices were still well above US prices in PPP terms in all poor countries throughout the period under study. Prices in \$US decreased due to two factors: (1) the introduction of cheaper local and generic brands in local markets; and (2) firms’ difficulties in increasing nominal prices when local currencies depreciated. Patients do not, however, benefit from decreasing prices in nominal local currency terms, but benefit from decreasing prices in real terms because of firms’ inability to increase nominal prices to offset the negative impact of local inflation. Drug firms appear to use the “skimming strategy” when pricing new drugs in patent regimes.

5 References

- Bagwell K. and M. H. Riordan (1991) ‘High and Declining Prices Signal Product Quality’, *American Economic Review*, 81, 224-239.
- Balasubramaniam T. (2000) ‘Background Information on Fourteen FDA Approved HIV/AIDS Drugs’, Consumer Project on Technology. Published online: <http://www.cptech.org/>, version 1.41, June 8 2000.

- 1
2
3 Berndt, E.R., Z. Griliches and J. Rosett (1993) 'Auditing the Producer Price Index: Micro
4 Evidence from Prescription Pharmaceutical Preparations, *Journal of*
5 *Business & Economic Statistics*, 11(3), 251-64.
6
7 Berndt E.R., *et al.* (1995) 'Information, Marketing, and Pricing in the U.S. Anti-ulcer
8 Drug Market', *American Economic Review*, 85(2), 100-105.
9
10 Berndt E.R., I.M. Cockburn and Z. Griliches, Zvi (1996) 'Pharmaceutical Innovations
11 and Market Dynamics: Tracing Effects on Price Indexes for
12 Antidepressant Drugs' *Brookings Papers on Economic Activity: Microeconomics*,
13 133-88.
14
15 Berndt E.R., Pindyck R.S. and Azoulay P. (1999) 'Network Effects and Diffusion in
16 Pharmaceutical Markets: Anti-ulcer Drugs, *NBER Working Papers*, 7024.
17
18 Berndt E.R., Pindyck R.S. and Azoulay P. (2000) 'Consumption Externalities and
19 Diffusion in Pharmaceutical Markets: Anti-ulcer Drugs', *NBER Working*
20 *Papers*, 7772.
21
22 Borrell J.R. and J. Watal (2002) 'Impact of Patents on Access to HIV/AIDS Drugs in
23 Developing Countries', CID Working Paper, No. 92, Center for
24 International Development, Harvard University.
25
26 Brazilian Ministry of Health (2001) '*Acesso Universal e Gratuito*', Coordenacao Nacional de
27 DST e AIDS, Secretaria de Politicas de Saude, Ministerio da Saude.
28 Published on-line at: <http://www.aids.gov.br>
29
30 Caves R.E., M.D. Whinston and M.A. Hurwitz (1991) 'Patent expiration, entry and
31 competition in the US pharmaceutical industry', *Brookings Papers on*
32 *Economic Activity: Microeconomics*, 1-48.
33
34 Challu P. (1991) 'The Consequences of Pharmaceutical Product Patenting', *World*
35 *Competition*, 15(2), 65-126.
36
37 Cockburn I.M. and A.H. Anis (1998) 'Hedonic Analysis of Arthritis Drugs', *NBER*
38 *Working Paper*, 6574.
39
40 Diwan I. and D. Rodrik D. (1991) 'Patents, Appropriate Technology, and North-South
41 Trade', *Journal of International Economics*, 30, 27-48.
42
43 FDA (2000) *Electronic Orange Book. Approved Drug Products with Therapeutic Evaluations*, US
44 Department of Health and Human Services, Federal Drug
45 Administration, Rockville, (MD, USA). Published online:
46 <http://www.fda.gov/cder/ob>.
47
48 Fink, C. (2000) 'How Stronger Patent Protection in India Might Affect the Behavior of
49 Transnational Pharmaceutical Industries', *World Bank Policy Research Paper*,
50 2352.
51
52 Fisher F.M. and Z. Griliches (1995) 'Aggregate price indices, new goods, and generics',
53 *Quarterly Journal of Economics*, 110(1), 229-244.
54
55 Frank R.G. and D.S. Salkever (1992) 'Pricing, patent loss and the market for
56 pharmaceuticals', *Southern Economic Journal*, 59(2), 165-179.
57
58 Frank R.G. and D.S. Salkever (1997) 'Generic entry and the pricing of pharmaceuticals',
59 *Journal of Economics and Management Strategy*, 6(1), 75-90.
60

- 1
2
3 Grabowski H.G. and J.M. Vernon (1992) 'Brand loyalty, entry, and price competition in
4 pharmaceuticals after the 1984 drug act', *Journal of Law and Economics*, 35,
5 331-350.
6
7 Griliches Z. and I. Cockburn (1994) 'Generics and new goods in pharmaceutical price
8 indexes', *The American Economic Review*, 84(5), 1213-1232.
9
10 Hellerstein J.K. (1994) 'The demand for post-patent prescription pharmaceuticals',
11 *NBER Working Paper*, 4981.
12
13 Henkel, J. (1999) 'Attacking AIDS with a "Cocktail" Therapy', *FDA Consumer Magazine*,
14 July-August 1999.
15
16 Hudson J. (1992) 'Pricing dynamics in the pharmaceutical industry', *Applied Economics*, 24,
17 103-112.
18
19 Hudson J. (2000) 'Generic Take-up in the Pharmaceutical Market Following Patent
20 Expiry: A Multi-Country Study', *International Review of Law and Economics*,
21 24, 103-112.
22
23 Hurwitz M.A. and R.E. Caves (1988) 'Persuasion or Information? Promotion and shares
24 of brand name and generic pharmaceuticals', *Journal of Law and Economics*,
25 31(2), 299-320.
26
27 IMF (2001) *International Finance Statistics*, CD-Rom edition, Produced by Joint IMF and
28 World Bank CD-ROM Project, Washington, D.C.
29
30 Lu Z. J. and Comanor W. S. (1998) 'Strategic Pricing of New Pharmaceuticals', *The Review*
31 *of Economics and Statistics*, 80 (1), 108-18.
32
33 Maskus, K.E and D. Eby-Konan (1994) 'Trade-Related Issues of Intellectual Property
34 Rights: Issues and Exploratory Results', in A.V. Deardorff and R.M. Stern
35 (Eds.) *Analytical and Negotiating Issues in the Global Trading System*, University
36 of Michigan Press, Ann Arbor (MI, USA)
37
38 PDR (2000) *Physicians' Desk Reference: PDR*, 54th Edition, Medical Economics, Oradell
39 (NJ, USA).
40
41 PDR-Generics (1997) *Physicians Desk Reference Generics*, 3rd Edition, Medical Economics,
42 Montvale (NJ, USA).
43
44 PDR-CG (1998) *Physicians Desk Reference Companion Guide*, 54th Edition, Medical
45 Economics, Montvale (NJ, USA).
46
47 PDR-CG (1999) *Physicians Desk Reference Companion Guide*, 54th Edition, Medical
48 Economics, Montvale (NJ, USA).
49
50 PDR-CG (2000) *Physicians Desk Reference Companion Guide*, 54th Edition, Medical
51 Economics, Montvale (NJ, USA).
52
53 Qian, Yi (2001) 'Do Additional National Patents Law Stimulate Domestic Innovation in
54 a Global Patenting Environment. A Cross-country Analysis of
55 Pharmaceutical Patent Protection: 1978-1999', unpublished dissertation,
56 Harvard College.
57
58 *Red Book* (1995) *Drug Topics Red Book.*, Medical Economics, Montvale (NJ, USA).
59
60 *Red Book* (1996) *Drug Topics Red Book.*, Medical Economics, Montvale (NJ, USA).
Red Book (1998) *Drug Topics Red Book.*, Medical Economics, Montvale (NJ, USA).
Red Book (1999) *Drug Topics Red Book.*, Medical Economics, Montvale (NJ, USA).

- 1
2
3 Scherer F.M. (1993) 'Pricing, profits and technological progress in the pharmaceutical
4 industry', *Journal of Economic Perspectives*, 7(3), 97-115.
5
6 Scherer F.M. and J. Watal (2001) 'Post-TRIPS options for access to patented medicines
7 in developing countries', a paper prepared for Working Group 4,
8 Commission for Macroeconomics and Health, World Health
9 Organization, mimeo.
10
11 Schemalensee, R. 'Product Differentiation, Advantages of Pioneering Brands', *American*
12 *Economic Review*, 72, 349-365.
13
14 Shapiro C. (1983) 'Optimal Pricing of Experience Goods', *Bell Journal of Economics*, 14,
15 497-507.
16
17 Subramanian, A. (1995) 'Putting Some Numbers on the TRIPS Pharmaceutical' Debate,
18 *International Journal of Technology Management*, 10, 252-68.
19
20 UNDP/UNU/WIDER (2000) 'World Income Inequality Database', Joint Project of the
21 United Nations Development Program (UNDP) and the United Nations
22 University/World Institute for Development Economics Research
23 (UNU/WIDER). Published online: <http://www.wider.unu.edu>, version
24 1.0, updated September 12 2000.
25
26 USDHHS/HKFF (2000) 'Guidelines for the Use of Antiretroviral Agents in HIV-
27 Infected Adults and Adolescents', US Department of Health and Human
28 Services and Henry J. Kaiser Family Foundation. Published online:
29 <http://www.hivatis.org>, January 28, 2000.
30
31 Watal, J. (2000) 'Pharmaceutical Patents, Prices and Welfare Losses: A Simulation Study
32 of Policy Options for India under the WTO TRIPS Agreement', *The*
33 *World Economy*, 23(5), 173-752.
34
35 Watal, J. (2001) 'Workshop on Differential Pricing and Financing of Essential Drugs:
36 Background Note', WTO, mimeo, available at
37 www.wto.org/english/tratop_e/trips_e/wto_background_e.doc.
38
39 WHO (2000) 'ATC classification index with Daily Defined Doses 2000', Excel file,
40 World Health Organization Collaborating Center for Drugs Statistics
41 Methodology, Oslo (Norway).
42
43 World Bank (2000a) *World Development Indicators 2000*, Washington DC. World Bank
44 (2000b) *World Development Report 2000-2001: Attaching Poverty*, Washington
45 DC.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

6 Tables

Table 1. ARV's approved in the US by June 2000 (from older to newer in the US)

Molecule generic name	Drug type	Brand name in the US	Firm name in the US	Year of key patent application	Launch Year in the US
ZIDOVUDINE (AZT)	NRTI	Retrovir ®	Glaxo Wellcome	1985	1987
DIDANOSINE (DDI)	NRTI	Videx ®	Bristol-Myer	1987	1991
ZALCITABINE (DDC)	NRTI	Hivid ®	Roche Labs	1987	1992
STAVUDINE (D4T)	NRTI	Zerit ®	Bristol-Myer	1986	1994
LAMIVUDINE (3TC)	NRTI	Epivir ®	Glaxo Wellcome	1989	1995
SAQUINAVIR	PI	Invirase ® and Fortovase ®	Roche Labs	1990	1995
INDINAVIR	PI	Crixivan ®	Merck	1993	1996
NEVIRAPINE	NNRTI	Viramune ®	Roxane	1993	1996
RITONAVIR	PI	Norvir ®	Abott Pharm	1995	1996
DELAVIRDINE	NNRTI	Rescriptor ®	Agouron	1994	1997
LAMIVUDINE & ZIDOVUDINE	NRTI	Combivir ®	Glaxo Wellcome	1989	1997
NELFINAVIR	PI	Viracept ®	Agouron	1994	1997
ABACAVIR	NRTI	Ziagen ®	Glaxo Wellcome	1989	1998
EFAVIRENZ	NNRTI	Sustiva ®	Du Pont Pharm.	1995	1998
AMPRENAVIR	PI	Agenerase ®	Glaxo Wellcome	1993	1999

Source: PDR (2000), Balasubramaniam (2000), and FDA (2000).

Table 2. - Number of drugs for which the innovator
could obtain patent or EMR rights

	1995	1996	1997	1998	1999	2000
US	6	9	12	13	15	15
CENTRAL AMERICA	6	9	12	13	15	15
FRENCH WEST AFRICA	6	9	12	13	15	15
MALAYSIA	6	9	12	13	15	15
SOUTH AFRICA R&H	6	9	12	13	15	15
PHILIPPINES R&H	6	9	12	14	15	15
MEXICO	5	8	11	12	13	13
THAILAND R&H	4	7	10	11	13	13
INDONESIA R&H	2	5	8	10	11	11
CHILE	1	4	6	7	8	8
BRAZIL	0	1	4	4	4	4
ARGENTINA	0	1	4	4	4	4
BANGLADESH	0	1	4	4	4	4
COLOMBIA	0	1	4	4	4	4
DOMINICAN REPUBLIC	0	1	4	4	4	4
EGYPT	0	1	4	4	4	4
ECUADOR	0	1	4	4	4	4
INDIA	0	1	4	4	4	4
MOROCCO	0	1	4	4	4	4
PAKISTAN	0	1	4	4	4	4
PERU	0	1	4	4	4	4
TUNISIA	0	1	4	4	4	4
URUGUAY	0	1	4	4	4	4
VENEZUELA	0	1	4	4	4	4

n.d.: no data.

Source: Author's calculations based on local legislation,
Balasubramaniam (2000) and Qian (2001).

Table 3. - Number of drugs available by country and year
(of which under patent regime)

	1995	1996	1997	1998	1999
US	6 (6)	9 (9)	12 (12)	13 (13)	15 (15)
ARGENTINA	4 (0)	7 (1)	10 (2)	12 (3)	14 (4)
CHILE	0	1 (0)	5 (0)	9 (3)	12 (5)
COLOMBIA	1 (0)	4 (1)	6 (1)	10 (2)	12 (3)
THAILAND R&H	3 (1)	6 (4)	8 (6)	10 (8)	12 (10)
MEXICO	3 (2)	3 (2)	5 (4)	8 (7)	10 (9)
SOUTH AFRICA R&H	3 (3)	4 (4)	6 (6)	9 (9)	10 (10)
FRENCH WEST AFRICA	2 (2)	2 (2)	4 (4)	8 (8)	9 (9)
BRAZIL	1 (0)	4 (0)	4 (0)	5 (0)	7 (0)
MALAYSIA	1 (1)	2 (2)	5 (5)	6 (6)	7 (7)
URUGUAY	1 (0)	1 (0)	1 (0)	5 (1)	7 (2)
CENTRAL AMERICA	1 (1)	1 (1)	4 (4)	5 (5)	5 (5)
INDIA	n.d.	n.d.	1 (0)	2 (0)	5 (0)
VENEZUELA	0	0	2 (0)	3 (0)	5 (0)
PHILIPPINES R&H	1 (1)	2 (2)	2 (2)	3 (3)	4 (4)
DOMINICAN REPUBLIC	0	0	0	0	3 (0)
ECUADOR	0	1 (0)	1 (0)	1 (0)	3 (0)
PERU	0	0	1 (0)	3 (0)	3 (0)
INDONESIA R&H	1 (0)	3 (0)	4 (1)	2 (1)	2 (1)
BANGLADESH	0	0	0	0	0
EGYPT	0	0	0	0	0
MOROCCO	0	0	0	0	0
PAKISTAN	0	0	0	0	0
TUNISIA	0	0	0	0	0

n.d.: no data.

R&H: Retail & Hospital sales. Otherwise, retail sales only.

Source: Author's calculations based on IMS.

Table 4. - Wholesale minimum price for an annual ARV therapy in 1999 (tablets only)

	Single Therapy	Double Therapy	Triple Therapy (HAART)	Per Capita Income (PPP\$)
US	2533	5114	6770	31910
ARGENTINA	1567	3845	6632	11324
CHILE	1513	4825	6853	8370
SOUTH AFRICA R&H	835	2023	4366	8318
URUGUAY	1533	7941	..	8280
MALAYSIA	1247	3153	..	7963
MEXICO	1195	2589	8149	7719
BRAZIL	757	1982	3025	6317
COLOMBIA	1431	2862	7824	5709
THAILAND R&H	593	2029	4345	5599
VENEZUELA	1869	4432	6301	5268
DOMINICAN REPUBLIC	1290	4161	..	4653
PERU	1476	4061	..	4387
PHILIPPINES R&H	1915	4770	6685	3815
CENTRAL AMERICA	1181	3019	..	3545
EQUADOR	954	2692	..	2605
INDONESIA R&H	1299	3408	..	2439
INDIA	634	1319	7728	2149
FRENCH WEST AFRICA	1411	3363	6624	1092

HAART: Highly Active ARV Therapy

Source: Author's computations on the price of single double and triple clinically tested drug bundles that can be combined using the drugs available in each country in 1999 based on IM. Per capita incomes from World Bank (2000).

Table 5. - Sales weighted local to US price ratios

	At current \$US						At purchasing power parity				
	1995	1996	1997	1998	1999	2000	1995	1996	1997	1998	1999
URUGUAY	2.68	0.99	0.60	1.07	1.62	1.15	3.94	1.40	0.84	1.48	2.26
VENEZUELA	0.52	0.66	1.01	1.11	0.81	0.94	1.45
MEXICO	0.67	0.70	0.71	0.66	0.74	0.91	1.18	1.36	1.42	1.24	1.29
ARGENTINA	0.95	0.97	0.86	0.87	0.91	0.83	1.38	1.42	1.25	1.27	1.36
COLOMBIA	1.18	1.45	1.00	0.97	0.88	0.79	3.01	3.51	2.31	2.32	2.24
CHILE	..	1.13	0.90	0.76	0.79	0.73	..	1.92	1.57	1.25	1.41
INDONESIA R&H	1.06	0.89	0.70	0.33	0.68	0.69	2.91	2.36	2.01	1.88	2.86
CENTRAL AMERICA	0.78	0.79	0.87	0.66	0.67	0.66	1.89	1.87	1.94	1.41	1.50
EQUADOR	..	0.84	0.74	0.57	0.62	0.59	..	1.66	1.45	1.13	1.24
FRENCH WEST AFRICA	1.15	1.10	0.88	0.63	0.60	0.57	3.31	3.08	2.55	1.80	1.72
DOMINICAN REPUBLIC	0.65	0.56	1.59
PERU	0.77	0.69	0.57	0.53	1.32	1.17	1.06
PHILIPPINES R&H	1.02	0.98	0.89	0.54	0.58	0.53	3.42	3.11	2.96	2.22	2.17
THAILAND R&H	0.81	0.77	0.62	0.52	0.55	0.50	1.78	1.68	1.56	1.57	1.57
MALAYSIA	0.86	0.81	0.67	0.53	0.50	0.47	1.65	1.51	1.31	1.32	1.17
BRAZIL	0.88	0.73	0.64	0.55	0.42	0.44	1.31	1.02	0.87	0.78	0.60
SOUTH AFRICA R&H	0.87	0.73	0.69	0.53	0.44	0.38	1.94	1.81	1.68	1.40	1.17
INDIA	n.d.	n.d.	0.63	0.42	0.30	0.20	n.d.	n.d.	2.91	1.99	1.43

n.d.: no data.

..: no drug available.

Author's calculations based on IMS, WHO (2000), *Red Book* (1995, 1996, 1997, 1998, 1999, 2000), PDR-Generics (1997) and PDR-CG (1998, 1999, 2000).

Table 6. - Drivers of Pricing Dynamics in \$US
(annual cumulative change between 1995 and 1999)¹

	Mean price in \$US	Entry & Mix	ARV price index in \$US	Local Currency
INDIA	-30.50%	-22.36%	-8.14%	-8.16%
SOUTH AFRICA R&H	-16.45%	-4.81%	-11.65%	-12.22%
URUGUAY	-15.29%	-13.76%	-1.53%	-7.65%
PERU	-15.23%	-3.60%	-11.63%	-11.26%
FRENCH WEST AFRICA	-14.81%	-11.10%	-3.72%	-26.22%
MALAYSIA	-14.72%	-11.96%	-2.75%	-9.90%
BRAZIL	-10.87%	-0.01%	-10.86%	-15.67%
PHILIPPINES R&H	-8.36%	2.67%	-11.03%	-9.94%
COLOMBIA	-7.91%	-8.29%	0.38%	-15.09%
CHILE	-7.13%	0.79%	-7.92%	-9.22%
THAILAND R&H	-6.96%	-2.26%	-4.70%	-9.90%
CENTRAL AMERICA	-6.86%	10.67%	-17.53%	-6.14%
ECUADOR	-5.78%	-5.78%
INDONESIA R&H	-2.08%	4.46%	-6.54%	-33.19%
ARGENTINA	2.08%	0.93%	1.14%	0.01%
MEXICO	3.45%	-0.51%	3.96%	-9.48%
VENEZUELA	27.33%	28.57%	-1.24%	-10.18%

¹ Or between the first year when any of the ARV's is locally available and 1999.

..: not available.

Source: Author's calculations based on IMS, WHO (2000), PDR (2000), IMF (2001).

Table 7. - Drivers of Pricing Dynamics in Local Currency
(annual cumulative change in the following factors)

	Relative Price Index in Local Currency	Nominal Price Index in Local Currency	Inflation Shocks on Relative Prices in Local Currency
FRENCH WEST AFRICA	-49.95%	22.51%	-72.46%
CENTRAL AMERICA	-20.65%	-11.39%	-9.27%
VENEZUELA	-15.96%	8.95%	-24.91%
PHILIPPINES R&H	-9.00%	-1.09%	-7.90%
INDIA	-7.15%	0.03%	-7.18%
SOUTH AFRICA R&H	-7.09%	0.58%	-7.67%
MEXICO	-5.98%	13.43%	-19.41%
INDONESIA R&H	-5.03%	26.65%	-31.68%
PERU	-4.73%	-0.36%	-4.37%
BRAZIL	-4.52%	4.81%	-9.33%
CHILE	-3.26%	1.29%	-4.55%
URUGUAY	-1.08%	6.12%	-7.20%
COLOMBIA	-0.82%	15.47%	-16.29%
THAILAND R&H	1.66%	5.21%	-3.54%
MALAYSIA	2.01%	7.15%	-5.13%
ARGENTINA	2.28%	1.14%	1.14%
ECUADOR

..: drugs available only two in 1998 and 1999.

Source: Author's calculations based on IMS, WHO (2000), PDR (2000).

Table 8. - Summary Statistics
 Observations: 2,459 single, double and triple drug bundles in 23 countries or
 regions that combine 14 different drugs between 1995 and 1999

Variable	Mean	Std. Dev.	Min	Max
Price per minimum daily dose	20.66	20.59	0.13	141.97
Drugs in Patent Regimes (%)	0.37	0.39	0.00	1.00
Original Brands (%)	0.71	0.34	0.00	1.00
Original drugs in patent regimes (%)	0.32	0.38	0.00	1.00
Country Mean Income	8684.47	3023.32	1092.00	11844.00
Country Income Inequality (Gini, %)	49.28	5.61	36.45	64.33
Including an oral liquid	0.37	0.48	0.00	1.00
Including a vial	0.04	0.19	0.00	1.00
2 drugs	0.58	0.49	0.00	1.00
3 drugs	0.18	0.39	0.00	1.00
Number of Doses a Day	4.47	1.87	1.00	12.00
Efficacy	0.21	0.24	-0.14	0.90
Adverse Reactions	0.09	0.05	0.00	0.29
Retail and Hospital sales	0.21	0.41	0.00	1.00
First year on the US market	0.04	0.19	0.00	1.00
Second year on the US market	0.24	0.43	0.00	1.00
Third year on the US market	0.17	0.38	0.00	1.00
Fourth year on the US market	0.14	0.34	0.00	1.00
Fifth year on the US market	0.14	0.35	0.00	1.00
Sixth year on the US market	0.03	0.17	0.00	1.00
Seventh year on the US market	0.04	0.19	0.00	1.00
Eighth year on the US market	0.06	0.23	0.00	1.00
Ninth year on the US market	0.08	0.27	0.00	1.00
Tenth year on the US market	0.01	0.12	0.00	1.00
Eleventh year on the US market	0.02	0.13	0.00	1.00
Twelfth year on the US market	0.02	0.14	0.00	1.00

Table 9. - Drug Bundle Pricing Regressions – OLS
 Coefficient (Standard Errors)
 Single, Double and Triple Therapy (n=2,459)

	Log of Price per Daily Dose of a Drug Bundle					
	(1)		(2)		(3)	
Local copies in no-patent regime	-- --		-- --		-- --	
Original drug in patent regime	.34 (.17)	+	.56 (.07)	**	.53 (.08)	**
Original drug in no-patent regime	.12 (.12)		.16 (.12)		.15 (.12)	+
Generics after patent expiration	.09 (.16)		.06 (.07)		.19 (.07)	**
Log of Country Mean Income	.23 (.08)	**	.23 (.51)		.32 (.06)	**
Country Income Inequality (Gini, %)	-1.15 (.48)		5.96 (1.56)	**		
Number of Doses per Day	.17 (.04)	**	.13 (.04)	**	.13 (.04)	**
Efficacy	.42 (.10)	**	.20 (.15)		.17 (.14)	
Adverse Reactions	-1.63 (.63)	*	-.84 (.23)	**	-.73 (.23)	**
Years in the US market:						
First	-- --		-- --		-- --	
Second	-.12 (.04)	**	-.19 (.07)	*	-.15 (.26)	
Third	-.14 (.07)	*	-.18 (.08)	*	-.13 (.08)	
Fourth	-.31 (.09)	**	-.27 (.07)	**	-.10 (.11)	
Fifth	-.33 (.09)	**	-.27 (.09)	**	-.21 (.07)	**
Sixth	-.18 (.10)	+	-.19 (.12)		-.22 (.05)	**
Seventh	-.25 (.10)	**	-.22 (.11)	+	-.13 (.08)	+
Eighth	-.30 (.14)	+	-.28 (.11)	**	-.16 (.08)	*
Ninth	-.36 (.12)	**	-.36 (.10)	**	-.25 (.09)	**
Tenth	.17 (.10)		.06 (.11)		-.32 (.08)	**
Eleventh	.11 (.08)		.03 (.09)		.16 (.08)	+
Twelfth	.05 (.07)		.05 (.08)		.13 (.06)	*
Fixed Effects:						
Pharmaceutical Form	Yes		Yes		Yes	
Number of Drugs	Yes		Yes		Yes	
Year	Yes		Yes			
Country			Yes			
Country-Year					Yes	
R ²	.64		.71		.73	

Hospital sales fixed effects included.

Robust Standard Errors Clustered on Country.

Significant at 1% (**), 5% (*), or 10% (+).

Table 10. - Drug Bundle Pricing Regressions – OLS
Coefficient (Standard Errors)

	Log of Price per Daily Dose of a Drug Bundle		
	Single Therapy (n=586)	Double Therapy (n=1,428)	Triple Therapy (n=445)
Local copies in no-patent regime	-- --	-- --	-- --
Original drug in patent regime	.62 (.11) **	.48 (.06) **	.63 (.05) **
Original drug in no-patent regime	.29 (.15) +	.11 (.08) +	
Generics after patent expiration	.25 (.09) *		
Number of Doses per Day	.14 (.08) +	.20 (.07) **	-.01 (.01)
Efficacy	.33 (.24)	-.01 (.13)	1.02 (.18) **
Adverse Reactions	.07 (.88)	.88 (.62)	-.66 (.50)
Years in the US market:			
First	-- --	-- --	-- --
Second	-.04 (.09)	-.22 (.15)	-.36 (.02) **
Third	.03 (.13)	-.25 (.16)	
Fourth	-.15 (.10)	-.34 (.20)	-.06 (.05)
Fifth	-.15 (.07) *	-.40 (.27)	-.02 (.05)
Sixth	-.15 (.10)	-.21 (.18)	
Seventh	-.30 (.10) **	-.21 (.21)	
Eighth	-.39 (.15) *	-.30 (.22)	
Ninth	-.49 (.15) **	-.43 (.28)	
Tenth	.16 (.11)		
Eleventh	.13 (.11)		
Twelfth	.06 (.13)		
Fixed Effects:			
Pharmaceutical Form	Sí	Sí	Sí
Number of Drugs	Sí	Sí	Sí
Country-Year	Sí	Sí	Sí
R ²	.51	.41	.27

Hospital sales fixed effects included.

Robust Standard Errors Clustered on Country.

Significant at 1% (**), 5% (*), or 10% (+).

Table 11. – Mean Price Differences by Patent Regime and Licensing Status

A. - All sample: Single, Double and Triple Therapy (n=2,459)			
Local copies in no-patent regime	100		
Original drug in patent regime	170 (**)	100	
Original drug in no-patent regime	116 (+)		
Generics after patent expiration	122 (**)	72	
B. - Single therapy (n=586)			
Local copies in no-patent regime	100		
Original drug in patent regime	186 (**)		
Original drug in no-patent regime	135 (+)		
Generics after patent expiration	127 (*)		
C. - Double therapy (n=1428)			
Local copies in no-patent regime	100		
Original drug in patent regime	162 (**)		
Original drug in no-patent regime	112		
Generics after patent expiration			
D. - Triple therapy (n=445)			
Local copies in no-patent regime	100		
Original drug in patent regime	188 (**)		
Original drug in no-patent regime			
Generics after patent expiration			

From the estimates including country-year fixed effects. Price differences with respect to the no-patent and unlicensed brand (local firm) are statistically significant at 1% (**), 5% (*), or 10% (+).

Fig 1. Daily Price Across Time Since US Launch Date
Bands: 95% prediction conf. interval

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

